GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » Return-on-Tangible-Equity

3SBio, (FRA:YFK) Return-on-Tangible-Equity : 1,354.04% (As of Dec. 2016)


View and export this data going back to . Start your Free Trial

What is 3SBio, Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 3SBio,'s annualized net income for the quarter that ended in Dec. 2016 was €116.6 Mil. 3SBio,'s average shareholder tangible equity for the quarter that ended in Dec. 2016 was €8.6 Mil. Therefore, 3SBio,'s annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2016 was 1,354.04%.

The historical rank and industry rank for 3SBio,'s Return-on-Tangible-Equity or its related term are showing as below:

FRA:YFK' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.39   Med: 12.93   Max: 53.75
Current: 43.44

During the past 13 years, 3SBio,'s highest Return-on-Tangible-Equity was 53.75%. The lowest was 4.39%. And the median was 12.93%.

FRA:YFK's Return-on-Tangible-Equity is not ranked
in the Biotechnology industry.
Industry Median: -47.81 vs FRA:YFK: 43.44

3SBio, Return-on-Tangible-Equity Historical Data

The historical data trend for 3SBio,'s Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, Return-on-Tangible-Equity Chart

3SBio, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec14 Dec15 Dec16
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.77 8.25 38.15 21.75 29.37

3SBio, Semi-Annual Data
Jun06 Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.51 20.11 12.39 23.76 1,354.04

Competitive Comparison of 3SBio,'s Return-on-Tangible-Equity

For the Biotechnology subindustry, 3SBio,'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio,'s Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio,'s Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where 3SBio,'s Return-on-Tangible-Equity falls into.



3SBio, Return-on-Tangible-Equity Calculation

3SBio,'s annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2016 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=97.62/( (649.9+14.771 )/ 2 )
=97.62/332.3355
=29.37 %

3SBio,'s annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2016 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2016 )  (Q: Jun. 2016 )(Q: Dec. 2016 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2016 )  (Q: Jun. 2016 )(Q: Dec. 2016 )
=116.644/( (2.4580000000001+14.771)/ 2 )
=116.644/8.6145000000001
=1,354.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2016) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


3SBio,  (FRA:YFK) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


3SBio, Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of 3SBio,'s Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio, (FRA:YFK) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines